Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy (Q38208280)

31 August 2017

title

Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy (English)

1 reference

31 August 2017

Lei Zhang

1 reference

31 August 2017

Yantao Han

1 reference

31 August 2017

Qixiao Jiang

1 reference

31 August 2017

Chunbo Wang

1 reference

31 August 2017

Xuehong Chen

1 reference

31 August 2017

Xiaoguang Li

1 reference

31 August 2017

Fuming Xu

1 reference

31 August 2017

Yuqi Jiang

1 reference

31 August 2017

Qiang Wang

1 reference

31 August 2017

Wenfang Xu

1 reference

31 August 2017

publication date

29 April 2014

1 reference

Medicinal Research Reviews

31 August 2017

published in

1 reference

31 August 2017

1 reference

31 August 2017

1 reference

31 August 2017

page(s)

63-84

1 reference

Genomewide studies of histone deacetylase function in yeast

31 August 2017

cites work

1 reference

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

Dissecting the biological functions of Drosophila histone deacetylases by RNA interference and transcriptional profiling.

21 January 2018

1 reference

Sirtuins: Sir2-related NAD-dependent protein deacetylases

21 January 2018

1 reference

Coactivator-dependent acetylation stabilizes members of the SREBP family of transcription factors.

21 January 2018

1 reference

Histone metabolic pathways and chromatin assembly factors as proliferation markers

21 January 2018

1 reference

Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation

21 January 2018

1 reference

Post-translational modification of p53 in tumorigenesis

21 January 2018

1 reference

Shaping the nuclear action of NF-kappaB

21 January 2018

1 reference

Evaluation of Histone Deacetylase Inhibitors as Therapeutics for Neurodegenerative Diseases

21 January 2018

1 reference

Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise

21 January 2018

1 reference

Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection

21 January 2018

1 reference

Histone deacetylase 6 regulates human immunodeficiency virus type 1 infection

21 January 2018

1 reference

HIV-1 Tat upregulates expression of histone deacetylase-2 (HDAC2) in human neurons: implication for HIV-associated neurocognitive disorder (HAND).

21 January 2018

1 reference

Histone deacetylase inhibitors and HIV latency

21 January 2018

1 reference

Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression

21 January 2018

1 reference

Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure

21 January 2018

1 reference

Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop

21 January 2018

1 reference

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain

21 January 2018

1 reference

MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation

21 January 2018

1 reference

Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo

21 January 2018

1 reference

Regulation of human SRY subcellular distribution by its acetylation/deacetylation

21 January 2018

1 reference

Stat3 dimerization regulated by reversible acetylation of a single lysine residue

21 January 2018

1 reference

Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation

21 January 2018

1 reference

Regulation of activity of the transcription factor GATA-1 by acetylation

21 January 2018

1 reference

Functional regulation of GATA-2 by acetylation

21 January 2018

1 reference

Regulation of E2F1 activity by acetylation

21 January 2018

1 reference

Acetylation of MyoD directed by PCAF is necessary for the execution of the muscle program

21 January 2018

1 reference

Regulation of transcription factor YY1 by acetylation and deacetylation

21 January 2018

1 reference

Acetylation of HMG I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome

21 January 2018

1 reference

Coordination of a transcriptional switch by HMGI(Y) acetylation

21 January 2018

1 reference

Modulation of HMG-N2 binding to chromatin by butyrate-induced acetylation in human colon adenocarcinoma cells

21 January 2018

1 reference

Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65

21 January 2018

1 reference

p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation

21 January 2018

1 reference

Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor

21 January 2018

1 reference

Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation

21 January 2018

1 reference

Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function

21 January 2018

1 reference

Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity

21 January 2018

1 reference

Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor α

21 January 2018

1 reference

Acetylation of GATA-3 affects T-cell survival and homing to secondary lymphoid organs

21 January 2018

1 reference

Acetylation and modulation of erythroid Krüppel-like factor (EKLF) activity by interaction with histone acetyltransferases

21 January 2018

1 reference

Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation

21 January 2018

1 reference

Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation

21 January 2018

1 reference

The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60

21 January 2018

1 reference

Control of Smad7 stability by competition between acetylation and ubiquitination

21 January 2018

1 reference

Site-specific acetylation by p300 or CREB binding protein regulates erythroid Krüppel-like factor transcriptional activity via its interaction with the SWI-SNF complex

21 January 2018

1 reference

Acetylation of importin-alpha nuclear import factors by CBP/p300.

21 January 2018

1 reference

Duration of nuclear NF-kappaB action regulated by reversible acetylation

21 January 2018

1 reference

Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis

21 January 2018

1 reference

HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor

21 January 2018

1 reference

Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code

21 January 2018

1 reference

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

21 January 2018

1 reference

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

21 January 2018

1 reference

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

21 January 2018

1 reference

The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor

21 January 2018

1 reference

Structural Biasing Elements for In-Cell Histone Deacetylase Paralog Selectivity

21 January 2018

1 reference

Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group

21 January 2018

1 reference

Identification of novel isoform-selective inhibitors within class I histone deacetylases

21 January 2018

1 reference

Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor

21 January 2018

1 reference

A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas

21 January 2018

1 reference

Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries

21 January 2018

1 reference

Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.

21 January 2018

1 reference

Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly.

21 January 2018

1 reference

Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays

21 January 2018

1 reference

Structural origin of selectivity in class II-selective histone deacetylase inhibitors

21 January 2018

1 reference

Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A

21 January 2018

1 reference

Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.

21 January 2018

1 reference

Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease

21 January 2018

1 reference

Discovery of the first histone deacetylase 6/8 dual inhibitors

21 January 2018

1 reference

A history of cancer chemotherapy

21 January 2018

1 reference

Timeline: Chemotherapy and the war on cancer.

21 January 2018

1 reference

Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.

21 January 2018

1 reference

Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma

21 January 2018

1 reference

The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy

21 January 2018

1 reference

The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo

21 January 2018

1 reference

Molecular aspects of resistance to antitumor platinum drugs.

21 January 2018

1 reference

Particular aspects of platinum compounds used at present in cancer treatment

21 January 2018

1 reference

Molecular aspects of antitumor effects of a new platinum(IV) drug.

21 January 2018

1 reference

A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity.

21 January 2018

1 reference

Novel trans-platinum complexes of the histone deacetylase inhibitor valproic acid; synthesis, in vitro cytotoxicity and mutagenicity

21 January 2018

1 reference

Conjugate of Pt(IV)-histone deacetylase inhibitor as a prodrug for cancer chemotherapy.

21 January 2018

1 reference

IMP dehydrogenase: structure, mechanism, and inhibition

21 January 2018

1 reference

An insight to the dynamics of conserved water molecular triad in IMPDH II (human): recognition of cofactor and substrate to catalytic Arg 322.

21 January 2018

1 reference

Identification of IMPDH2 as a tumor-associated antigen in colorectal cancer using immunoproteomics analysis

21 January 2018

1 reference

Studies in the biochemistry of micro-organisms. 86. The molecular constitution of mycophenolic acid, a metabolic product of Penicillium Brevi-compactum Dierckx. Part III. Further observations on the structural formula for mycophenolic acid

21 January 2018

1 reference

Mycophenolic acid-induced replication arrest, differentiation markers and cell death of androgen-independent prostate cancer cells DU145.

21 January 2018

1 reference

Differentiation of human prostate cancer PC-3 cells induced by inhibitors of inosine 5'-monophosphate dehydrogenase.

21 January 2018

1 reference

Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment

21 January 2018

1 reference

Structure-activity relationships for inhibition of inosine monophosphate dehydrogenase and differentiation induction of K562 cells among the mycophenolic acid derivatives.

21 January 2018

1 reference

Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level.

21 January 2018

1 reference

Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylase based on a cinnamic hydroxamic acid core structure.

21 January 2018

1 reference

The protein tyrosine kinase family of the human genome

21 January 2018

1 reference

Receptor tyrosine kinases and targeted cancer therapeutics

21 January 2018

1 reference

Targeted cancer therapies in the twenty-first century: lessons from imatinib

21 January 2018

1 reference

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (d

21 January 2018

1 reference

Sorafenib: a review of its use in advanced hepatocellular carcinoma

21 January 2018

1 reference

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

21 January 2018

1 reference

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

21 January 2018

1 reference

Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis

21 January 2018

1 reference

Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis

21 January 2018

1 reference

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

21 January 2018

1 reference

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

21 January 2018

1 reference

Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases

21 January 2018

1 reference

Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity

21 January 2018

1 reference

Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer

21 January 2018

1 reference

CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity

21 January 2018

1 reference

Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion

21 January 2018

1 reference

DNA topoisomerases: structure, function, and mechanism

21 January 2018

1 reference

DNA topoisomerases and their poisoning by anticancer and antibacterial drugs

21 January 2018

1 reference

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

21 January 2018

1 reference

Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors

21 January 2018

1 reference

Estrogen and estrogen receptors in cardiovascular oxidative stress

21 January 2018

1 reference

Cardiovascular roles of estrogen receptors: insights gained from knockout models

21 January 2018

1 reference

Estrogen receptors alpha and beta in choroid plexus epithelial cells in Alzheimer's disease.

21 January 2018

1 reference

Estrogen receptors: role in breast cancer.

21 January 2018

1 reference

Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance

21 January 2018

1 reference

Histone deacetylase inhibitors equipped with estrogen receptor modulation activity.

21 January 2018

1 reference

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.47.301

Identifiers

DOI

10.1002/MED.21320

1 reference

31 August 2017

1 reference